Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia

被引：0
|
作者：
Yoji Ishida
Kazunori Murai
Kohei Yamaguchi
Takuto Miyagishima
Motohiro Shindo
Kazuei Ogawa
Takahiro Nagashima
Shinji Sato
Reiko Watanabe
Satoshi Yamamoto
Takayuki Hirose
Souich Saitou
Masakatsu Yonezumi
Takeshi Kondo
Yuichi Kato
Noboru Mochizuki
Keiko Ohno
Satoshi Kishino
Kohmei Kubo
Tatsuo Oyake
Shigeki Ito
机构：
[1] Iwate Medical University School of Medicine,Saitama Medical Center
[2] Aomori Prefectural Central Hospital,Department of Hematology and Oncology, Internal Medicine
[3] Kushiro Rosai Hospital,undefined
[4] Asahikawa Medical University School of Medicine,undefined
[5] Fukushima Medical University School of Medicine,undefined
[6] Kitami Red Cross Hospital,undefined
[7] Okitama Public General Hospital,undefined
[8] Saitama Medical University,undefined
[9] Sapporo City General Hospital,undefined
[10] Niigata Cancer Center Hospital,undefined
[11] Nihonkai General Hospital,undefined
[12] Hokkaido Cancer Center,undefined
[13] Hokkaido University School of Medicine,undefined
[14] Yamagata University Faculty of Medicine,undefined
[15] Meiji Pharmaceutical University,undefined
[16] Iwate Medical University School of Medicine,undefined
来源：
European Journal of Clinical Pharmacology | 2016年 / 72卷
关键词：
Dasatinib; Phamacokinetics; Pharmacodynamics; Molecular response; Half maximal inhibitory concentration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 193
页数：8
相关论文
共 50 条
  • [41] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Tokuhira, Michihide
    Kimura, Yuta
    Sugimoto, Keiji
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujioka, Isao
    Takaku, Tomoiku
    Iriyama, Noriyoshi
    Sato, Eriko
    Fujita, Hiroyuki
    Hatta, Yoshihiro
    Komatsu, Norio
    Asou, Norio
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [42] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Fallah, P.
    Amirizadeh, N.
    Poopak, B.
    Toogeh, G.
    Arefian, E.
    Kohram, F.
    Rad, S. M. A. Hosseini
    Kohram, M.
    Naghadeh, H. Teimori
    Soleimani, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (04) : 560 - 568
  • [44] Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study
    Iwamoto, Takuya
    Monma, Fumihiko
    Ohishi, Kohshi
    Umino, Akira
    Suzuki, Kei
    Oka, Koji
    Kawakami, Keiki
    Sekine, Takao
    Okuda, Masahiro
    Katayama, Naoyuki
    THERAPEUTIC DRUG MONITORING, 2019, 41 (05) : 575 - 581
  • [45] Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?
    Quintas-Cardama, Alfonso
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2007, 48 (03) : 445 - 446
  • [46] Asciminib in Newly Diagnosed Chronic Myeloid Leukemia Reply
    Abruzzese, Elisabetta
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (23): : 2276 - 2276
  • [47] Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
    Klink, Andrew J.
    Keating, Scott J.
    Brokars, John
    Feinberg, Bruce
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 149 - 157
  • [48] Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
    Hjorth-Hansen, H.
    Stentoft, J.
    Richter, J.
    Koskenvesa, P.
    Hoeglund, M.
    Dreimane, A.
    Porkka, K.
    Gedde-Dahl, T.
    Gjertsen, B. T.
    Gruber, F. X.
    Stenke, L.
    Eriksson, K. M.
    Markevarn, B.
    Lubking, A.
    Vestergaard, H.
    Udby, L.
    Bjerrum, O. W.
    Persson, I.
    Mustjoki, S.
    Olsson-Stromberg, U.
    LEUKEMIA, 2016, 30 (09) : 1853 - 1860
  • [49] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [50] Early results of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
    Naqvi, Kiran
    Jabbour, Elias
    Skinner, Jeffrey
    Yilmaz, Musa
    Ferrajoli, Alessandra
    Bose, Prithviraj
    Thompson, Philip
    Alvarado, Yesid
    Jain, Nitin
    Takahashi, Koichi
    Burger, Jan
    Estrov, Zeev
    Borthakur, Gautam
    Pemmaraju, Naveen
    Paul, Shilpa
    Cortes, Jorge
    Kantarjian, Hagop M.
    CANCER, 2018, 124 (13) : 2740 - 2747
12345